By Michele Maatouk
Date: Tuesday 31 Mar 2026
(Sharecast News) - Shares in Apellis Pharmaceuticals rocketed on Tuesday after it agreed to be bought by Biogen in a $5.6bn deal.
| Currency | US Dollars |
| Share Price | $ 199.95 |
| Change Today | $ -6.04 |
| % Change | -2.93 % |
| 52 Week High | $216.28 |
| 52 Week Low | $122.68 |
| Volume | 962,710 |
| Shares Issued | 146.80m |
| Market Cap | $29,353m |
| RiskGrade | 259 |
| Time | Volume / Share Price |
| 15:59 | 200 @ $199.75 |
| 15:59 | 100 @ $199.77 |
| 15:59 | 100 @ $199.78 |
| 15:59 | 200 @ $199.94 |
| 15:59 | 100 @ $199.87 |
You are here: research